Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intercept Pharma (NASDAQ: ICPT), MacroGenics (NASDAQ: MGNX) and Tactile Systems Technology (NASDAQ: TCMD)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intercept Pharma (NASDAQ: ICPT), MacroGenics (NASDAQ: MGNX) and Tactile Systems Technology (NASDAQ: TCMD).

Intercept Pharma (NASDAQ: ICPT)

In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Hold rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $58. The company’s shares opened today at $68.84.

Piros observed:

“PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH.”

According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -4.1% and a 47.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $109.17, representing a 58.6% upside.

In a report issued on May 2, Oppenheimer also assigned a Hold rating to the stock.

See today’s analyst top recommended stocks >>

MacroGenics (NASDAQ: MGNX)

BTIG analyst Dane Leone maintained a Buy rating on MacroGenics (NASDAQ: MGNX) yesterday and set a price target of $28. The company’s shares opened today at $21.37.

Leone said:

“Cancer On Monday post-market close, MGNX reported 1Q18 financials and updated expected clinical milestones for the remainder of 2018. We remain Buy rated into ASCO, as we are generally positive on the potential combo of margetuximab + pembro for HER2+ gastric cancer, and think that the updated clinical data at ASCO during the first weekend of June could be a positive catalyst for the stock. That said, updates on other key clinical programs suggest a slower path forward (details below).”

According to TipRanks.com, Leone is a 5-star analyst with an average return of 18.3% and a 69.4% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and Blueprint Medicines.

Currently, the analyst consensus on MacroGenics is Strong Buy and the average price target is $31.67, representing a 48.2% upside.

In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $34 price target.

Tactile Systems Technology (NASDAQ: TCMD)

In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Tactile Systems Technology (NASDAQ: TCMD), with a price target of $42. The company’s shares opened today at $37.80.

Lavin observed:

“Expanding Salesforce; PT to $42 from $40 TCMD reported a $3M revenue beat vs consensus, helped by a strong contribution from sales into the VA medical channel and the bolus of sales reps hired near the end of 2017. The revenue guidance range for the year was raised by $1M to $132-$134M (prior $131-$133M). In our preview when we raised our PT to $40, we said we felt year-long guidance may be exceeded. We also view this new target as conservative, given this quarter’s result. We continue to believe TCMD will post beats throughout 2018 and we lift our sales forecast accordingly. With a higher revenue forecast, we move our price target to $42 from $40.”

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 15.1% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.

Tactile Systems Technology has an analyst consensus of Strong Buy, with a price target consensus of $39.88.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts